This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.66

A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis

Yi-Long Wu, Haiyan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, Chi Leung Lam, BJ Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Jean Fan, David Kuo, Yu Wang, Kaimin Pang, Caicun Zhou

Wu 1200.66 Poster_WCLC 2017

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park K, et al. Lancet Oncol 2016;17(5):577–89

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu Y-L, et al. Lancet Oncol 2014;15(2):213–22

Related information

WCLC 2017

Find information on afatinib and nintedanib's clinical data and Boehringer Ingelheim's activities at WCLC 2017

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy
Back to top